Simultaneous Targeting of PD-1 and IL-2Rβγ with Radiation Therapy Inhibits Pancreatic Cancer Growth and Metastasis

The bispecific PD1-IL2v is a PD-1-targeted interleukin-2 variant (IL-2v) immunocytokine with engineered IL-2 cis targeted to PD-1 and abolished IL-2Rα binding, which enhanced tumor-antigen-specific T cell activation, while reducing regulatory Treg suppression.